300. Pharmacy Tools for Investigational Drug Studies feat. Dr. Michael Schlesselman

Pharmacy, IT, & Me: Your Informatics Pharmacist Podcast

300. Pharmacy Tools for Investigational Drug Studies feat. Dr. Michael Schlesselman

Intended Audience: Everyone

Originally recorded early 2022

Investigational drug services and studies are a complicated beast. How does pharmacy informatics and technology play a role?

On today's episode, Dr. Michael Schlesselman joins us to discuss how we can leverage technology to help improve the investigational drug study and research world with electronic documentation and tracking. On this episode:

• Dr. Schlesselman's journey to where he is today
• How Vestigo as an investigational drug software helps with inventory tracking and sponsor audits
• The training that one may need to get into the vendor side of pharmacy informatics
• Finding the right residency for you

To reach out to Dr. Schlesselman, you can email him at [e-mail] or visiting his LinkedIn at https://www.linkedin.com/in/michael-schlesselman-7a65805/

Disclaimer: Views expressed are those of the individuals and do not reflect thoughts and opinions of any entity with which speakers have been, is now, or will be affiliated.
New to LinkedIn and not sure where to start? Download my free ebook, "Professional Networking Unlocked", at https://www.tonydaopharmd.com/ebook
Follow us on social media!
Twitter: @pharmacyitme
Instagram: @pharmacyinformatics
LinkedIn: https://www.linkedin.com/company/pharmacyitme/
Website: Pharmacy IT & Me
Email: [e-mail]
Follow Tony's personal Twitter account at @tonydaopharmd
Network with other pharmacists at Pharmacists Connect!
http://pharmacistsconnect.com
For more information on pharmacy informatics, check out some of the following useful links:
ASHP's Section of Pharmacy Informatics and Technology: https://www.ashp.org/Pharmacy-Informaticist/Section-of-Pharmacy-Informatics-and-Technology/
HIMSS: https://www.himss.org/resources/pharmacy-informatics-and-its-cross-functional-role-healthcare
Disclaimer: Views expressed are my own and do not reflect thoughts and opinions of any entity with which I have been, am now, or will be affiliated.